BRTX logo

BioRestorative Therapies (BRTX) Cash From Operations

Annual CFO

-$6.43 M
-$517.10 K-8.74%

December 1, 2023


Summary


Performance

BRTX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherBRTXcash flowmetrics:

Quarterly CFO

-$1.70 M
+$165.60 K+8.88%

September 1, 2024


Summary


Performance

BRTX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherBRTXcash flowmetrics:

TTM CFO

-$7.47 M
-$520.20 K-7.48%

September 1, 2024


Summary


Performance

BRTX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherBRTXcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

BRTX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-8.7%0.0%0.0%
3 y3 years-227.3%0.0%0.0%
5 y5 years-26.0%0.0%0.0%

BRTX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-93.1%at low-48.4%+28.6%-124.3%at low
5 y5-year-227.3%+7.1%-304.3%+28.6%-280.3%at low
alltimeall time-781.8%+7.1%-518.9%+28.6%-779.0%at low

BioRestorative Therapies Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$1.70 M(-8.9%)
-$7.47 M(+7.5%)
Jun 2024
-
-$1.87 M(-19.5%)
-$6.95 M(+9.1%)
Mar 2024
-
-$2.32 M(+46.0%)
-$6.37 M(-1.0%)
Dec 2023
-$6.43 M(+8.7%)
-$1.59 M(+34.6%)
-$6.43 M(-0.4%)
Sep 2023
-
-$1.18 M(-8.1%)
-$6.46 M(-4.0%)
Jun 2023
-
-$1.28 M(-46.1%)
-$6.73 M(+0.5%)
Mar 2023
-
-$2.38 M(+47.3%)
-$6.70 M(+13.3%)
Dec 2022
-$5.91 M(+77.6%)
-$1.62 M(+11.3%)
-$5.91 M(+8.6%)
Sep 2022
-
-$1.45 M(+16.0%)
-$5.44 M(+17.8%)
Jun 2022
-
-$1.25 M(-21.5%)
-$4.62 M(+12.4%)
Mar 2022
-
-$1.59 M(+39.3%)
-$4.11 M(+23.5%)
Dec 2021
-$3.33 M(+69.5%)
-$1.15 M(+81.9%)
-$3.33 M(+20.8%)
Sep 2021
-
-$629.40 K(-15.2%)
-$2.76 M(+4.0%)
Jun 2021
-
-$741.80 K(-8.8%)
-$2.65 M(+13.8%)
Mar 2021
-
-$813.70 K(+42.2%)
-$2.33 M(+18.6%)
Dec 2020
-$1.96 M(-71.6%)
-$572.10 K(+9.4%)
-$1.96 M(-38.7%)
Sep 2020
-
-$523.10 K(+24.4%)
-$3.20 M(-27.0%)
Jun 2020
-
-$420.40 K(-6.3%)
-$4.39 M(-18.5%)
Mar 2020
-
-$448.60 K(-75.2%)
-$5.39 M(-22.1%)
Dec 2019
-$6.92 M(+35.5%)
-$1.81 M(+5.9%)
-$6.92 M(+3.9%)
Sep 2019
-
-$1.71 M(+20.7%)
-$6.66 M(+5.7%)
Jun 2019
-
-$1.42 M(-28.4%)
-$6.30 M(+6.4%)
Mar 2019
-
-$1.98 M(+27.5%)
-$5.93 M(+16.1%)
Dec 2018
-$5.10 M(+32.5%)
-$1.55 M(+14.8%)
-$5.10 M(+3.9%)
Sep 2018
-
-$1.35 M(+30.0%)
-$4.91 M(+20.7%)
Jun 2018
-
-$1.04 M(-10.2%)
-$4.07 M(+7.2%)
Mar 2018
-
-$1.16 M(-14.8%)
-$3.79 M(-1.6%)
Dec 2017
-$3.85 M
-$1.36 M(+167.0%)
-$3.85 M(+8.4%)
DateAnnualQuarterlyTTM
Sep 2017
-
-$509.20 K(-33.5%)
-$3.56 M(-16.4%)
Jun 2017
-
-$766.00 K(-37.2%)
-$4.25 M(-5.6%)
Mar 2017
-
-$1.22 M(+14.8%)
-$4.50 M(-10.0%)
Dec 2016
-$5.00 M(+60.2%)
-$1.06 M(-11.9%)
-$5.00 M(+0.2%)
Sep 2016
-
-$1.21 M(+18.5%)
-$5.00 M(+14.2%)
Jun 2016
-
-$1.02 M(-40.8%)
-$4.37 M(+5.0%)
Mar 2016
-
-$1.72 M(+63.0%)
-$4.17 M(+33.4%)
Dec 2015
-$3.12 M(-3.3%)
-$1.05 M(+80.6%)
-$3.12 M(+15.5%)
Sep 2015
-
-$583.60 K(-27.9%)
-$2.70 M(-8.5%)
Jun 2015
-
-$809.60 K(+20.0%)
-$2.95 M(-4.6%)
Mar 2015
-
-$674.80 K(+6.4%)
-$3.10 M(-4.1%)
Dec 2014
-$3.23 M(+20.8%)
-$634.30 K(-23.9%)
-$3.23 M(-3.9%)
Sep 2014
-
-$833.70 K(-12.5%)
-$3.36 M(+13.5%)
Jun 2014
-
-$953.20 K(+18.2%)
-$2.96 M(+9.3%)
Mar 2014
-
-$806.70 K(+5.6%)
-$2.71 M(+1.3%)
Dec 2013
-$2.67 M(-16.1%)
-$763.80 K(+75.8%)
-$2.67 M(-10.7%)
Sep 2013
-
-$434.40 K(-38.2%)
-$2.99 M(-0.5%)
Jun 2013
-
-$702.50 K(-9.0%)
-$3.01 M(-15.6%)
Mar 2013
-
-$771.80 K(-28.7%)
-$3.56 M(+11.9%)
Dec 2012
-$3.18 M(+13.3%)
-$1.08 M(+140.1%)
-$3.18 M(-1.0%)
Sep 2012
-
-$450.90 K(-64.1%)
-$3.22 M(+5.8%)
Jun 2012
-
-$1.26 M(+219.0%)
-$3.04 M(+29.1%)
Mar 2012
-
-$393.90 K(-64.7%)
-$2.35 M(-16.2%)
Dec 2011
-$2.81 M(+285.5%)
-$1.12 M(+306.2%)
-$2.81 M(+65.8%)
Sep 2011
-
-$274.60 K(-51.9%)
-$1.70 M(+19.3%)
Jun 2011
-
-$570.80 K(-32.8%)
-$1.42 M(+67.2%)
Mar 2011
-
-$849.90 K
-$849.90 K
Dec 2010
-$729.20 K
-
-

FAQ

  • What is BioRestorative Therapies annual cash flow from operations?
  • What is the all time high annual CFO for BioRestorative Therapies?
  • What is BioRestorative Therapies annual CFO year-on-year change?
  • What is BioRestorative Therapies quarterly cash flow from operations?
  • What is the all time high quarterly CFO for BioRestorative Therapies?
  • What is BioRestorative Therapies quarterly CFO year-on-year change?
  • What is BioRestorative Therapies TTM cash flow from operations?
  • What is the all time high TTM CFO for BioRestorative Therapies?
  • What is BioRestorative Therapies TTM CFO year-on-year change?

What is BioRestorative Therapies annual cash flow from operations?

The current annual CFO of BRTX is -$6.43 M

What is the all time high annual CFO for BioRestorative Therapies?

BioRestorative Therapies all-time high annual cash flow from operations is -$729.20 K

What is BioRestorative Therapies annual CFO year-on-year change?

Over the past year, BRTX annual cash flow from operations has changed by -$517.10 K (-8.74%)

What is BioRestorative Therapies quarterly cash flow from operations?

The current quarterly CFO of BRTX is -$1.70 M

What is the all time high quarterly CFO for BioRestorative Therapies?

BioRestorative Therapies all-time high quarterly cash flow from operations is -$274.60 K

What is BioRestorative Therapies quarterly CFO year-on-year change?

Over the past year, BRTX quarterly cash flow from operations has changed by $0.00 (0.00%)

What is BioRestorative Therapies TTM cash flow from operations?

The current TTM CFO of BRTX is -$7.47 M

What is the all time high TTM CFO for BioRestorative Therapies?

BioRestorative Therapies all-time high TTM cash flow from operations is -$849.90 K

What is BioRestorative Therapies TTM CFO year-on-year change?

Over the past year, BRTX TTM cash flow from operations has changed by $0.00 (0.00%)